International journal of urology : official journal of the Japanese Urological Association 2023 Jun 06
Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease.
Related Questions
KEYNOTE-564 required CrCl 30 or above. Not having a baseline/stable CrCl may make it difficult to diagnose or treat IO nephritis.
New answer by Medical Oncologist at Huntsman Cancer Institute - University of Utah Health Care (April 14, 2024)
My preference in situations like this is to stabilize the renal function first. I am comfortable treating the patient with adjuvant pembrolizumab with a CrCl <30 mL/min but...